NCT/Study#
NCT05514717 /
MER-XMT-2056-1
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants with Advanced/Recurrent Solid Tumors that Express HER2
DISEASE GROUP:
Breast Cancer Clinical Trials
current phase:
Phase I
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
